Bioventus, a leader in active orthopaedic healing, today announced agreement
with Pfizer Inc. PFE for an exclusive, worldwide license to Pfizer's bone
morphogenetic protein (BMP) portfolio of development programs and associated
intellectual property. The portfolio includes a next-generation BMP in
development, designed to offer additional options to currently-marketed BMP
products, and the rights to rhBMP-2 in indications and fields previously
reserved to Pfizer. Bioventus has also acquired an exclusive option to a BMP
program for soft tissue indications.
Pfizer has agreed to transfer to Bioventus all existing development work for
the BMP assets and to undertake certain early-development activities relating
to the next-generation BMP. Pfizer will also manufacture rhBMP-2 and supply it
to Bioventus.
To lead the BMP programs, Bioventus has retained the services of distinguished
BMP scientists Dr. John Wozney and Dr. Howard Seeherman. Bioventus is opening
a research laboratory in Boston, MA to pursue development and
commercialization of the BMP assets.
Under the terms of the license agreement, Pfizer received an upfront payment
and will be eligible to receive milestone payments and royalties on any sales.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in